Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Rhodes Pharmaceuticals

Pharmaceutical intelligence for Rhodes Pharmaceuticals with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
5
Assets
5

Recent signals(5)

RegulatoryJune 28, 2026

FDA Approval Letter for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen by Rhodes Pharmaceuticals.

RegulatoryJune 26, 2026

FDA Approves Supplemental Application for Dilaudid by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Dilaudid, containing hydromorphone hydrochloride.

RegulatoryJune 26, 2026

FDA Approves Supplement for Morphine Sulfate by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Morphine Sulfate submitted by Rhodes Pharmaceuticals.

RegulatoryJune 25, 2026

FDA Approves Oxycodone Hydrochloride Supplement by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Oxycodone Hydrochloride submitted by Rhodes Pharmaceuticals.

RegulatoryJune 24, 2026

FDA Accepts Supplemental NDA for Dilaudid by Rhodes Pharmaceuticals

The FDA has accepted a supplemental NDA for Dilaudid, an opioid pain medication.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(5)

RegulatoryJune 28, 2026

FDA Approval Letter for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen by Rhodes Pharmaceuticals.

RegulatoryJune 26, 2026

FDA Approves Supplemental Application for Dilaudid by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Dilaudid, containing hydromorphone hydrochloride.

RegulatoryJune 26, 2026

FDA Approves Supplement for Morphine Sulfate by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Morphine Sulfate submitted by Rhodes Pharmaceuticals.

RegulatoryJune 25, 2026

FDA Approves Oxycodone Hydrochloride Supplement by Rhodes Pharmaceuticals

The FDA has approved a supplemental application for Oxycodone Hydrochloride submitted by Rhodes Pharmaceuticals.

RegulatoryJune 24, 2026

FDA Accepts Supplemental NDA for Dilaudid by Rhodes Pharmaceuticals

The FDA has accepted a supplemental NDA for Dilaudid, an opioid pain medication.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Dilaudid →
FDA →
Morphine Sulfate →
Oxycodone Hydrochloride →
Regulatory Approval →

Therapeutic areas

Opioid →
Opioid Combination →
Pain Management →
Pain Management · Opioid →
Pain Management · Opioid Combination →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.